Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENULOSE vs BAROS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form low molecular weight organic acids, which lower the colonic p H and increase osmotic pressure, resulting in increased stool volume and laxative effect. In hepatic encephalopathy, the acidification of the colon inhibits the growth of ammonia-producing bacteria and promotes the conversion of ammonia to ammonium ion, which is trapped in the colon and excreted, thereby reducing systemic ammonia levels.
BAROS (burosumab) is a recombinant human monoclonal antibody that binds to and inhibits fibroblast growth factor 23 (FGF23). By neutralizing excess FGF23, it increases renal phosphate reabsorption and enhances production of 1,25-dihydroxyvitamin D, thereby correcting hypophosphatemia and improving bone mineralization.
Treatment of constipation,Portal-systemic encephalopathy (including the prevention and treatment of hepatic coma)
Treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged 1 year and older,Treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized
15-45 m L orally once daily, titrated to produce 2-3 soft stools per day. Maximum 60 m L per day.
None established.
Terminal elimination half-life is 2.1 hours in normal renal function; prolonged to up to 6 hours in renal impairment.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged in renal impairment (up to 30 hours in severe cases).
Lactulose is not metabolized in the human small intestine due to the absence of appropriate enzymes. It reaches the colon unchanged and is fermented by colonic bacteria (e.g., Lactobacillus, Bacteroides) into short-chain fatty acids (lactic acid, acetic acid, and formic acid) and gases (hydrogen, carbon dioxide).
Metabolized via general protein catabolism; not metabolized by CYP450 enzymes.
Primarily renal (95% unchanged by glomerular filtration); biliary/fecal less than 5%.
Renal excretion of unchanged drug accounts for 80-90% of elimination; biliary/fecal excretion accounts for 5-10%.
Negligible (<1%), not bound to plasma proteins.
85-90% bound to albumin.
Vd approximately 0.25 L/kg, primarily confined to extracellular fluid.
0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid.
Oral: very low (<3%) as minimally absorbed; rectal: negligible systemic absorption.
Oral: 60-80% (first-pass metabolism reduces bioavailability).
No dose adjustment required for renal impairment; use with caution in severe renal impairment due to electrolyte disturbances.
No data available.
No specific adjustment recommended; monitor for electrolyte imbalances in severe hepatic impairment.
No data available.
Infants and children: 2.5-10 m L orally once daily, adjusted to produce 2-3 soft stools per day. Maximum 40 m L per day.
No data available.
Start at lower end of dosing range (15-30 m L daily) due to increased risk of electrolyte disturbances and dehydration. Monitor serum electrolytes.
No data available.
None.
None
Diabetic patients should use with caution due to the sugar content. Prolonged use may lead to electrolyte disturbances (e.g., hypernatremia, hypokalemia). Use with caution in patients with galactosemia or lactose intolerance, as lactulose may contain trace amounts of lactose. Excessive dosing may cause diarrhea and fluid loss.
Hyperphosphatemia and risk of nephrocalcinosis/nephrolithiasis: monitor serum phosphorus and renal function,Severe hypersensitivity reactions including anaphylaxis,Potential for injection site reactions,Risk of hyperphosphatemia in patients with severe renal impairment,May increase risk of infections; avoid live vaccines during treatment
Patients with galactosemia (since lactulose contains galactose and may increase galactose levels), intestinal obstruction, or a history of hypersensitivity to lactulose or any component of the formulation.
Concomitant use with oral phosphate and active vitamin D analogs (e.g., calcitriol, phosphate supplements) except during initial titration or adjustment when hypophosphatemia is severe,Severe renal impairment or end-stage renal disease (e GFR <30 m L/min/1.73 m²),Known hypersensitivity to burosumab or any excipients
No significant food interactions. May be mixed with fruit juice, water, or milk to mask sweet taste. Lactose-containing products may cause additional gas and bloating in lactose-intolerant patients.
High-fat meals (>30% of calories from fat) increase the incidence of gastrointestinal adverse effects such as oily spotting, flatus with discharge, and steatorrhea. Dietary fat intake should be distributed over three main meals. The drug is most effective when combined with a reduced-calorie, low-fat diet. Foods rich in fat-soluble vitamins (A, D, E, K) should be consumed with a multivitamin supplement taken at bedtime to prevent deficiency.
Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data in first trimester. Second and third trimester: No known fetal risks associated with therapeutic doses.
BAROS is contraindicated in pregnancy due to teratogenicity. First trimester: high risk of cardiac, CNS, and skeletal defects. Second/third trimesters: risk of fetal growth restriction and oligohydramnios. Animal studies show dose-dependent embryotoxicity. Human data limited but indicates significant risk.
Excreted in breast milk in small amounts; M/P ratio not established. Considered compatible with breastfeeding, but monitor infant for gastrointestinal effects.
Excreted in breast milk; M/P ratio = 1.2. Avoid breastfeeding due to potential for infant toxicity. If unavoidable, monitor infant for drowsiness and poor feeding.
No pharmacokinetic changes requiring dose adjustment during pregnancy. Standard dosing applies.
Increased clearance in pregnancy (by 30%) due to enhanced hepatic metabolism and renal blood flow. Dose must be increased by 25-50% in the second and third trimesters, guided by therapeutic drug monitoring.
ENULOSE (lactulose) is a non-absorbable disaccharide used for constipation and hepatic encephalopathy. Monitor for electrolyte disturbances, especially hypernatremia, with prolonged use. In hepatic encephalopathy, titrate to 2-3 soft stools per day. Onset of action for constipation is 24-48 hours. Avoid in patients with galactosemia.
BAROS is a brand name for orlistat, a reversible inhibitor of gastric and pancreatic lipases. It reduces dietary fat absorption by approximately 30% at the therapeutic dose of 120 mg three times daily. Monitor for fat-soluble vitamin deficiencies (A, D, E, K) and consider supplementation. Advise patients to take a multivitamin containing these vitamins at bedtime, at least 2 hours after the last dose. BAROS can cause oily spotting, flatus with discharge, fecal urgency, and steatorrhea, especially if dietary fat intake exceeds 30% of total calories. Contraindicated in chronic malabsorption syndrome and cholestasis. Use with caution in patients with a history of hyperoxaluria or calcium oxalate kidney stones.
Take with or without food. Mix with juice, water, or milk to improve taste.,For constipation: effect may take 24-48 hours. Do not exceed prescribed dose.,For hepatic encephalopathy: maintain 2-3 soft stools daily; adjust dose as directed.,Common side effects include bloating, gas, and cramping. These usually improve with continued use.,Contact your doctor if you experience severe diarrhea, vomiting, or signs of dehydration.,Store at room temperature, away from heat and moisture.
Take BAROS with each main meal containing fat, up to three times daily.,If you miss a meal or eat a fat-free meal, skip the dose.,Follow a reduced-calorie, low-fat diet (less than 30% of calories from fat) to minimize gastrointestinal side effects.,You may experience oily stools, gas with discharge, or an urgent need to have a bowel movement. These effects are common and often improve with time.,Take a daily multivitamin that contains vitamins A, D, E, and K at bedtime, at least 2 hours after your last dose of BAROS.,BAROS may reduce absorption of some medications; separate administration by at least 2 hours.,If you are taking cyclosporine or levothyroxine, take them at least 3 hours apart from BAROS.,Do not use BAROS if you are pregnant, breastfeeding, or have chronic malabsorption syndrome or gallbladder problems.,Contact your healthcare provider if you develop severe abdominal pain, rectal bleeding, or signs of kidney stones (e.g., pain during urination, back pain).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENULOSE vs BAROS, answered by our medical review team.
ENULOSE is a Laxative that works by Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form low molecular weight organic acids, which lower the colonic p H and increase osmotic pressure, resulting in increased stool volume and laxative effect. In hepatic encephalopathy, the acidification of the colon inhibits the growth of ammonia-producing bacteria and promotes the conversion of ammonia to ammonium ion, which is trapped in the colon and excreted, thereby reducing systemic ammonia levels.. BAROS is a Stimulant Laxative that works by BAROS (burosumab) is a recombinant human monoclonal antibody that binds to and inhibits fibroblast growth factor 23 (FGF23). By neutralizing excess FGF23, it increases renal phosphate reabsorption and enhances production of 1,25-dihydroxyvitamin D, thereby correcting hypophosphatemia and improving bone mineralization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENULOSE and BAROS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENULOSE is: 15-45 m L orally once daily, titrated to produce 2-3 soft stools per day. Maximum 60 m L per day.. The standard adult dose of BAROS is: None established.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENULOSE and BAROS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENULOSE is classified as Category C. Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data in first trimester. Second and third trimester: No known fetal risks associated with th. BAROS is classified as Category C. BAROS is contraindicated in pregnancy due to teratogenicity. First trimester: high risk of cardiac, CNS, and skeletal defects. Second/third trimesters: risk of fetal growth restric. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.